Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Research Council grant · Running

Nano-BITE Multispecific theranostic nano-engager platform

Coordinator
Institut Gustave Roussy, France
Runs
1 December 2026 to 31 May 2028
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101335332

What the project is doing

In the project's own words, from its summary on CORDIS.

This ERC Proof of Concept proposal develops ""Nano-BITE,"" a multifunctional nanoparticle platform addressing limitations of current cancer immunotherapy. Existing bispecific antibodies like blinatumomab suffer from rapid kidney clearance due to small molecular size, requiring continuous intravenous infusion for weeks and showing poor efficacy in solid tumors. The Nano-BITE platform uses PLGA nanoparticles as scaffolds incorporating four integrated features: modular E3/K3 peptide chemistry enabling rapid attachment of nanobodies targeting NK cells and tumor antigens, extended circulation achieving greater than 24-hour half-life versus 7 hours for conventional engagers, localized IL-15 delivery for sustained NK cell activation within tumors without systemic toxicity, and integrated radioisotope chelators enabling PET imaging to track drug distribution and predict response.

The platform's innovative ""plug-and-play"" design allows rapid adaptation to different cancers by swapping targeting modules within hours rather than 18-24 months required for new drug development. When imaging reveals antigen switching, subsequent doses can target different antigens using the same nanoparticle backbone. The 18-month validation plan includes optimizing formulation and demonstrating superior NK cell activation in vitro, followed by proving therapeutic efficacy in humanized mouse models of HER2-positive breast cancer.

This approach could transform cancer immunotherapy from static treatments to dynamic platforms adapting to disease evolution, potentially capturing markets exceeding fifty billion dollars versus one to five billion for individual bispecifics.""

Topics

Who is involved

OrganisationCityCountryRole
Institut Gustave RoussyVillejuifFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI